Treatment of contaminated populations after a nuclear accident: Novel drugs designed by Medesis Pharma proved to be effective Recently published, a scientific article confirms the mode of action of nanoparticles designed by Medesis Pharma. The nanoparticles were made...
“A treatment for Alzheimer’s disease? ” Medesis Pharma announces a new therapeutic approach against Alzheimer’s disease with NP03 a lithium lipidic microemulsion formulation A preclinical study published in “Translational...
BACE1 inhibition by microdose lithium formulation NP03 rescues memory loss and early stage amyloid neuropathology EN Wilson, S Do Carmo, MF Iulita, H Hall, A Ducatenzeiler, AR Marks, S Allard, DT Jia, J Windheim and AC Cuello. Lithium is first-line therapy for bipolar...
The storage or technical access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication on an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.Technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance by your ISP, or additional third-party records, information stored or retrieved for this purpose alone generally cannot be used to identify you.
Storage or technical access is required to create user profiles to send advertising, or to track the user across one or multiple websites for similar marketing purposes.